on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics: Webcast on Lusvertikimab with Experts
OSE Immunotherapeutics SA announces a webcast scheduled for September 2, 2026. This event will focus on lusvertikimab, a drug for chronic inflammatory bowel diseases. Experts will discuss the biology of the IL-7 receptor and the results of the Phase 2 CoTiKis study in ulcerative colitis.
Professor Laurent Peyrin-Biroulet and Dr. Maia Kayal will participate in the discussion, along with Marc Le Bozec and Dr. Aurore Morello from the company. The discussions will also aim to define development prospects, particularly in chronic pouchitis. The webcast will be held live in English, with French subtitles available.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news